QMENTA's neuroimaging platform enables Parkinson's disease research through AI-powered MRI and PET biomarker analysis — including iron accumulation,...
Discover how the Central Vein Sign (CVS) — with 95% sensitivity and 92% specificity — is transforming MS diagnosis and how QMENTA powered the CAVS-MS...
Learn how to integrate AI tools into medical imaging workflows using QMENTA's cloud platform — covering benefits of AI in imaging, key challenges,...
Take a look ahead at our predicted trends for neuroscience in 2025 - where technology, neuroplasticity, and neuroethics are reshaping the way we...
Discover insights into structural and functional aspects of the human brain, potential biomarkers, and applications in psychiatric research.
QMENTA’s hybrid cloud imaging approach combines automated cloud processing with on-premise expert editing for higher accuracy, speed, and...
Compare 6 automated white matter lesion segmentation tools for MS available on QMENTA — including LST-LPA, mediaire Lesion Characterization, SAMSEG,...
Boston, MA, March 29, 2023— QMENTA, Inc. announced today that John E. Kelly III, PhD has been appointed to the company's Board of Advisors. Dr. Kelly...
It is difficult to diagnose Parkinson’s disease, and the only way to confirm diagnosis is postmortem. The new imaging AI tools could be the answer.